Bayer: darolutamide cut risk of metastasis or death by 58% in prostate cancer
Bayer says Nubeqa with ADT and radiation cut the risk of metastasis or death by 58% in high-risk recurrent prostate cancer. TradingView reported the data.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Bayer said NUBEQA (darolutamide), given with ADT and radiation, reduced the risk of metastasis or death by 58% versus placebo in high-risk recurrent prostate cancer. The hazard ratio was 0.42 with p=0.0001, at a median follow-up of 3.8 years. TradingView reported the results, citing Bayer's press release distributed by BusinessWire.
According to the company, the safety profile was consistent with earlier studies. Grade 3 or higher adverse events occurred in 43% of patients versus 36% on placebo. Overall survival data are not yet mature, and follow-up is ongoing.
why it matters
For Bayer, the result adds late-stage evidence in an earlier disease setting and widens the potential market for the drug. Still, immature overall survival data and a higher share of serious side effects could slow adoption and shape decisions by payers and guideline bodies.
market impact
BAYN: positive trial data widen Nubeqa's potential market, supporting expectations for the company's oncology business
tags
instruments
sources
- Bayer (BAYN) Darolutamide Cut Metastasis/Death Risk 58% in High‑Risk Prostate Cancer — TradingView, 24 October 2026 at 12:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗